clinical trial · NCT03083665
A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy
UCB Biopharma SRL·phase3·completed·n = 449
Partial Seizures With or Without Secondary GeneralizationEpilepsyPlaceboBrivaracetam
brief summary
The purpose of the study is to evaluate the efficacy of brivaracetam (BRV) compared to placebo (PBO) as adjunctive treatment in subjects (\>=16 to 80 years of age) with partial seizures with or without secondary generalization despite current treatment with 1 or 2 concomitant antiepileptic drugs (AEDs) and to assess the safety and tolerability of BRV in subjects \>= 16 years to 80 years of age.
started
Aug 22, 2017
primary completion
Jun 30, 2022
completion
Jun 30, 2022
last updated
Oct 14, 2025
official title
A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Adjunctive Brivaracetam in Subjects (>=16 to 80 Years of Age) With Partial Seizures With or Without Secondary Generalization
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol